GENZYME - THE KING OF THE BIOTECHS Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENZYME - THE KING OF THE BIOTECHS

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Vector1 who wrote (317)	7/29/1998 5:59:00 AM
From: Andreas Helke	Read Replies (1) of 410

I think that in a few years not using anti adhesion products will be considered to be unacceptable. I would be pretty pissed off if I had to undergo repeat surgery only because my surgeon did not use an available anti adhesion product. The bigger question of course is if Seprafilm is still the favoured product when anti adhesion usage finally catches on. I think just about any company that is working with hyaluronic acid has an anti adhesion development program. Anika claims that their not yet approved anti adhesion product works better than the current Seprafilm. Life Medical Sciences CHAI has an anti adhesion product from another base material that worked much better than Seprafilm in preclinical animal studies. CHAI will run out of cash in the next 3 months and its current market cap of $11 million is probably too low to raise the necessary development money by selling shares. A partnership or straight buyout is probably necessary to keep CHAI running in the long term. Maybe Genzyme should play it save and acquire the rights to this promising technology. Andreas

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next